Envoy Medical Inc (COCH)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$7.10-0.28%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · COCH
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 195.8% |
| Our one-year growth estimate | diamond | 26.3% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 169.5 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 29 industry peers
COCH — capital allocation — Material Modifications to Rights of Security Holders
Dated 2026-10-27
Material Modifications to Rights of Security Holders. To the extent required by
Why it matters: The trial's main test uses 12-month speech scores. These results will show whether Acclaim meets that test.
Watch forThe company reports that the trial met its primary speech-score goal using 12-month data.
Also watch forThe company reports that the trial missed its primary speech-score goal using 12-month data.
Why it matters: Envoy completed a 1-for-10 reverse split on October 26. Nasdaq compliance after the split remains unconfirmed in these inputs.
Watch forNasdaq confirms that COCH meets the $1.00 minimum bid-price rule and keeps its listing.
Also watch forNasdaq reports that COCH has not met the $1.00 rule or issues a new compliance notice.
Why it matters: Cash fell from $25.251 million in March to $19.679 million in June. More trial work and FDA filings need funding.
Worry ifA later report shows cash above $19.679 million, or new funding that covers trial costs through the final PMA filing.
Less concerning ifCash falls below $19.679 million with no new funding, or Envoy says its funds may not last through the final filing.
Why it matters: The report can update trial progress, PMA timing, and cash. Q2 revenue was just $51,000, so cash and spending matter.
Watch forThe report confirms that the trial remains on schedule, PMA filings stay on track, and cash is above $19.679 million.
Also watch forThe report cites a trial or filing delay, or cash below $19.679 million without new funding.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$215 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $688 loss on $10,000 · 6.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,401 loss on $10,000 · 54.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.